Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

September 22, 2022

https://www.globenewswire.com/news-release/2022/09/22/2520909/0/en/Medicenna-Presents-Preclinical-Data-Demonstrating-Anti-Tumor-Activity-of-its-Anti-PD1-IL-2-BiSKIT-and-Long-Acting-IL-4-IL-13-Super-antagonist-at-Cytokines-2022.html

— Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer

Read more at globenewswire.com

Related news for (MDNA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.